This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.Need a new registration confirmation email? Click here

Illumina Inc. (ILMN): Today's Featured Drugs Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Illumina (
ILMN) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole was unchanged today. By the end of trading, Illumina rose 82 cents (1.6%) to $51.82 on average volume. Throughout the day, 1.3 million shares of Illumina exchanged hands as compared to its average daily volume of 1.6 million shares. The stock ranged in a price between $50.55-$52.29 after having opened the day at $50.63 as compared to the previous trading day's close of $51. Other companies within the Drugs industry that increased today were:
Acura Pharmaceuticals (
ACUR), up 25.7%,
ARCA biopharma (
ABIO), up 13%,
China Pharma (
CPHI), up 10.2%, and
Dendreon (
DNDN), up 8%.

EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and biological function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $6.24 billion and is part of the health care sector. The company has a P/E ratio of 31.8, above the S&P 500 P/E ratio of 17.7. Shares are down 9% year to date as of the close of trading on Tuesday. Currently there are seven analysts that rate Illumina a buy, one analyst rates it a sell, and eight rate it a hold.

TheStreet Ratings rates Illumina as a
buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.